Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Chronic hypoxia- and monocrotaline-induced elevation of hypoxia-inducible factor-1α levels and pulmonary hypertension

Abstract

A close relationship exists between hypoxia-inducible factor (HIF)-1α and pulmonary hypertension. The present study was carried out to explore if there are temporal alterations in HIF-1α levels during prolonged hypoxia and after monocrotaline (MCT) treatment. First, young Wistar rats were divided into 5 groups: control, hypoxia-1, hypoxia-2, hypoxia-3 and hypoxia-4. Hypoxic rats were placed in a closed hypobaric chamber (380 mm Hg) for a 1-week (hypoxia-1), 2-week (hypoxia-2), 3-week (hypoxia-3) or 5-week (hypoxia-4) period. Second, other young Wistar rats were divided into 4 groups: control, MCT-1, MCT-2 and MCT-3. MCT-treated rats were injected subcutaneously once with MCT (60 mg/kg) for a 1-week (MCT-1), 2-week (MCT-2) or 3-week (MCT-3) period. Subsequently, pulmonary arterial pressure (Ppa) and the weight ratio of the right ventricle to the left ventricle plus the septum [RV/(LV + S)] were measured, and lungs were obtained for the determination of HIF-1α via Western blot analysis. Both hypoxia and MCT induced temporal increases in the Ppa, the ratio RV/(LV + S) and HIF-1α levels. A close relationship between the Ppa and HIF-1α level was found in both hypoxia- and MCT-treated animals. In addition, the PaO2 level significantly decreased in rats 1–3 weeks after MCT treatment. These results, along with previous data in the literature, suggest that both chronic hypoxia- and MCT-induced lung hypoxia activate an increase in the production of HIF-1α, and result in vascular remodeling and pulmonary hypertension.

This is a preview of subscription content, log in to check access.

References

  1. 1

    Atkinson JE, Olson JW, Altiere RJ, Gillespie MN. Evidence that hypoxic pulmonary vascular remodeling in rats is polyamine dependent. J Appl Physiol 62:1562–1568;1987.

  2. 2

    Chavez JC, Agani F, Pichiule P, LaManna JC. Expression of hypoxia-inducible factor-1α in the brain of rats during chronic hypoxia. J Appl Physiol 89:1937–1942;2000.

  3. 3

    Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J, Cicarlo VS, Oparil S. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol 29:713–725;1997.

  4. 4

    Lai Y-L, Olson JW, Gillespie MN. Ventilatory dysfunction precedes pulmonary vascular changes in monocrotaline-treated rats. J Appl Physiol 70:561–566;1991.

  5. 5

    Lai Y-L, Thacker AA, Diana JN. Hypoxemia and elevated tachykinins in rat monocrotaline pneumotoxicity. Lung 174:195–203;1996.

  6. 6

    Lai Y-L, Wu H-D, Chen C-F. Antioxidants attenuate chronic hypoxic pulmonary hypertension. J Cardiovasc Pharmacol 32:714–720;1998.

  7. 7

    Martin C, Yu AY, Jiang B-H, Davis L, Kimberly D, Hohimer AR, Semenza GL. Cardiac hypertrophy in chronically anemic fetal sheep: Increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1. Am J Obstet Gynecol 178:527–534;1998.

  8. 8

    Meyrick B, Reid L. The effect of continuous hypoxia on rat pulmonary arterial circulation: An ultrastructural study. Lab Invest 38:188–200;1978.

  9. 9

    Olson JW, Altiere RJ, Gillespie MN. Prolonged activation of rat lung ornithine decarboxylase in monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 33:3633–3637;1984.

  10. 10

    Olson JW, Atkinson JE, Hacker AD, Altiere RJ, Gillespie MN. Suppression of polyamine biosynthesis prevents monocrotaline-induced pulmonary edema and arterial medial thickening. Toxicol Appl Pharmacol 81:91–99;1985.

  11. 11

    Palmer LA, Semenza GL, Stoler MH, Johns RA. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol 274:L212-L219;1998.

  12. 12

    Rose F, Grimminger F, Appel J, Heller M, Pies V, Weissmann N, Fink L, Schmidt S, Krick S, Camenisch G, Gassmann M, Seeger W, Hanze J. Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: Role of hypoxia-inducible transcription factors. FASEB J 16:1660–1661;2002.

  13. 13

    Savourey G, Launay JC, Besnard Y, Guinet A, Travers S. Normo- and hypobaric hypoxia: Are there any physiological differences? Eur J Appl Physiol 89:122–126;2003.

  14. 14

    Semenza GL. Hypoxia-inducible factor 1: Master regulator of O2 homeostasis. Curr Opin Genet Dev 8:588–594;1998.

  15. 15

    Semenza GL. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88:1474–1480;2000.

  16. 16

    Sheedy W, Thompson JS, Morice AH. A comparison of pathophysiological changes during hypobaric and normobaric hypoxia in rats. Respiration 63:217–222;1996.

  17. 17

    Wang GL, Jiang B-H, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510–5514;1995.

  18. 18

    Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 275:L818-L826;1998.

  19. 19

    Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JSK, Wiener CM, Sylvester JT, Semenza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor-1α. J Clin Invest 103:691–696;1999.

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lai, Y., Law, T.C. Chronic hypoxia- and monocrotaline-induced elevation of hypoxia-inducible factor-1α levels and pulmonary hypertension. J Biomed Sci 11, 315–321 (2004). https://doi.org/10.1007/BF02254435

Download citation

Key WordsChronic hypoxia

  • Monocrotaline
  • Hypoxia-inducible factor
  • Pulmonary hypertension